Thumbnail Image
Item

Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours

Barszczewska-Pietraszek, Gabriela
; 
Drzewiecka, Małgorzata
; 
Czarny, Piotr
; 
Skorski, Tomasz
; 
Śliwiński, Tomasz
Citations
Altmetric:
Genre
Journal article
Date
2022-12-24
Advisor
Committee member
Group
Fels Cancer Institute for Personalized Medicine (Temple University)
Department
Cancer and Cellular Biology
Microbiology, Immunology and Inflammation
Subject
Polθ inhibitors
 Anticancer treatment
 DNA double-strand break repair
 DNA repair enzyme
Permanent link to this record
http://hdl.handle.net/20.500.12613/10116
Collections
Faculty/Researcher Works
Show all metadata
Files
Thumbnail Image
SkorskiEtAl-JournalArticle-2022-12.pdf
Adobe PDF, 1.21 MB
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.3390/ijms24010319
Abstract
DNA polymerase theta (Polθ)-mediated end joining (TMEJ) is, along with homologous recombination (HR) and non-homologous end-joining (NHEJ), one of the most important mechanisms repairing potentially lethal DNA double-strand breaks (DSBs). Polθ is becoming a new target in cancer research because it demonstrates numerous synthetically lethal interactions with other DNA repair mechanisms, e.g., those involving PARP1, BRCA1/2, DNA-PK, ATR. Inhibition of Polθ could be achieved with different methods, such as RNA interference (RNAi), CRISPR/Cas9 technology, or using small molecule inhibitors. In the context of this topic, RNAi and CRISPR/Cas9 are still more often applied in the research itself rather than clinical usage, different than small molecule inhibitors. Several Polθ inhibitors have been already generated, and two of them, novobiocin (NVB) and ART812 derivative, are being tested in clinical trials against HR-deficient tumors. In this review, we describe the significance of Polθ and the Polθ-mediated TMEJ pathway. In addition, we summarize the current state of knowledge about Polθ inhibitors and emphasize the promising role of Polθ as a therapeutic target.
Description
Citation
Barszczewska-Pietraszek, G.; Drzewiecka, M.; Czarny, P.; Skorski, T.; Śliwiński, T. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours. Int. J. Mol. Sci. 2023, 24, 319. https://doi.org/10.3390/ijms24010319
Citation to related work
MDPI
Has part
International Journal of Molecular Sciences, Vol. 24, Iss. 1
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
Embedded videos